CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
cediranib maleatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00309946
NCT00309946Phase 2Completed
CompareCT.gov

Phase II Study of AZD2171 (NSC#732208) in Patients With Malignant Mesothelioma

National Cancer Institute (NCI)·interventional·Posted Apr 3, 2006·Updated Jul 31, 2014

In Brief

A Phase 2 clinical trial evaluating cediranib maleate for Advanced Malignant Mesothelioma and 4 related conditions. Completed, enrolled 51 participants across 1 site.

Detailed Summary

This phase II trial is studying how well cediranib maleate works in treating patients with malignant mesothelioma that cannot be removed by surgery. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 3, 2006
Enrollment StartDec 1, 2005
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 20.2 years ago

Interventions

cediranib maleatedrug

Given orally